Netherlands· NL-f24c330bba05
Teysuno 15 mg/4,35 mg/11,8 mg harde capsules
A tegafur, kombinationen product containing gimeracil + oteracil kalium 0-water + tegafur, registered in Netherlands by Nordic Group BV. The same ATC class is registered in 9 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Tegafur, kombinationen is registered in 9 of 19 countries.
Countries holding a registration under ATC L01BC53 (tegafur, kombinationen), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 6 of them publish a price we can compare per daily dose
Tegafur, kombinationen · ATC L01BC53
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- GIMERACIL + OTERACIL KALIUM 0-WATER + TEGAFUR
- Manufacturer
- Nordic Group BV
- Country
- Netherlands (NL)
- ATC code
- L01BC53
- ATC class
- Tegafur, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/11/669
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Tegafur, kombinationen in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTEYSUNONordic Group BV, Hoofddorp
- SpainTEYSUNO 15 mg/4,35 mg/11,8 mg CAPSULAS DURASNordic Group B.V.
- United KingdomTeysuno 15mg/4.35mg/11.8mg capsulesNordic Pharma Ltd
- IrelandTeysuno 15 mg/4.35 mg/11.8 mg hard capsulesNordic Group B.V.
- IcelandTeysunoNordic Group BV
- NorwayTeysunoNordic Group BV
- PolandTeysunoNordic Group B.V.
- SwedenTeysuno 15 mg/4,35 mg/11,8 mg Kapsel, hårdNordic Group BV
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Teysuno
- Iceland · Teysuno
- Liechtenstein · Teysuno
- Norway · Teysuno
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dbf39e6e-4b94-4c87-9939-cfe9700bf6f1 GET /v1/drugs/dbf39e6e-4b94-4c87-9939-cfe9700bf6f1?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"route": "Oraal gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/teysuno-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Tegafur, Combinations",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp106311",
"excipients": [
"CARNAUBAWAS (E 903)",
"GELATINE (E 441)",
"GLYCERYLMONO-OLEAAT",
"GRIJZE INKT",
"IJZEROXIDE GEEL (E 172)",
"IJZEROXIDE ROOD (E 172)",
"IJZEROXIDE ROOD (E 172)",
"INDIGOKARMIJN ALUMINIUMLAK (E 132)",
"LACTOSE 1-WATER",
"MAGNESIUMSTEARAAT (E 470b)",
"NATRIUMLAURILSULFAAT",
"SCHELLAK (E 904)",
"TALK (E 553b)",
"TITAANDIOXIDE (E 171)"
],
"substances": [
"GIMERACIL",
"OTERACIL KALIUM 0-WATER",
"TEGAFUR"
],
"leaflet_url": null,
"authorised_at": "2011/03/14",
"procedure_number": "EMEA/H/C/001242",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/11/669",
"additional_monitoring": "N"
}See everything about tegafur, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.